Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Bristol Myers Squibb : to Take Part in Cowen and Company 37th Annual Global Health Care Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
02/27/2017 | 03:31pm CET

Bristol-Myers Squibb Company (NYSE: BMY) will present at the Cowen and Company 37th Annual Global Health Care Conference on Monday, March 6, 2017, in Boston. Giovanni Caforio, chief executive officer, will make a formal presentation about the company at 2:00 p.m. EST.

Investors and the general public are invited to listen to a live webcast of the presentation at http://investor.bms.com. Materials related to the presentation will be available at the same website at the start of the live webcast. An archived edition of the presentation will be available later that day.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, and YouTube.

© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
02/27 BRISTOL MYERS SQUIBB : to Take Part in Cowen and Company 37th Annual Global Heal..
02/27 BRISTOL MYERS SQUIBB CO : Other Events, Financial Statements and Exhibits (form ..
02/27 BRISTOL MYERS SQUIBB : Expands International Immuno-Oncology Network (II-ON) Wit..
02/27 BRISTOL MYERS SQUIBB : Exelixis and Bristol-Myers Squibb Enter Clinical Collabor..
02/24 BRISTOL MYERS SQUIBB : Findings from Bristol-Myers Squibb Reveals New Findings o..
02/24 BRISTOL MYERS SQUIBB : Researchers from Bristol-Myers Squibb Report Recent Findi..
02/24 BRISTOL MYERS SQUIBB : Trademark Application for "APOTHECON" Filed by Bristol-My..
02/24 BRISTOL MYERS SQUIBB : Findings from Bristol-Myers Squibb Update Understanding o..
02/23 BRISTOL MYERS SQUIBB : Prices $1.5 Billion of Senior Notes
02/22 Newmont and Papa John's dip; Bristol-Myers and Garmin rise
More news
Sector news : Pharmaceuticals - NEC
08:35aDJASTRAZENECA : FDA OKs Once-Daily Qtern for Type-2 Diabetes
02/27DJJOHNSON & JOHNSON : Prescription Unit List Prices Rose 8.5% Last Year
02/27 FTSE ends higher on some positive earnings, insurers slip
02/27DJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/24DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/27 Biotechs scorching today, IBB up 3%
02/27 ACADIA Pharma Looks Like A Take-Out Target
02/27 SNIPPET ROUNDUP : Cyclacel's Data Dredge And Bristol's Activist Investor
02/27 Bristol-Myers closes $1.5B debt offering
02/27 Roche's Renal Success Spells Danger For All-Comer Studies
Financials ($)
Sales 2017 19 720 M
EBIT 2017 5 198 M
Net income 2017 4 660 M
Finance 2017 422 M
Yield 2017 2,88%
P/E ratio 2017 20,45
P/E ratio 2018 18,77
EV / Sales 2017 4,78x
EV / Sales 2018 4,56x
Capitalization 94 609 M
More Financials
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 55,4 $
Spread / Average Target -2,1%
Consensus details
EPS Revisions
More Estimates Revisions
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON6.53%332 993
ROCHE HOLDING LTD.5.42%209 283
PFIZER INC.5.48%204 030
NOVARTIS AG4.72%203 039
MERCK & CO., INC.12.38%181 558
More Results